Use of (+)-(11R,2′S)-&agr;-2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol or a pharmaceutically acceptable salt thereof substantially free of its (−)-enantiomer in the manufacture of a medicament having reduced side-effect compared to the racemic (±)-(R*,S*)-&agr;-2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol for treating or preventing malaria in a subject. A method of treating or preventing malaria with reduced side-effects comprising administration of (+)-(11R,2′S)-&agr;-2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol or a pharmaceutically acceptable salt thereof substantially free of its (−)-enantiomer.
使用(+)-(11R,2′S)-α-2-
哌啶基-2,8-双(三
氟甲基)-
4-喹啉甲醇或其药学上可接受的盐,在制造一种药物中,该药物相对于光学混合物(±)-(R*,S*)-α-2-
哌啶基-2,8-双(三
氟甲基)-
4-喹啉甲醇,用于治疗或预防受试者患疟疾时具有减少副作用。一种治疗或预防疟疾的方法,包括给予(+)-(11R,2′S)-α-2-
哌啶基-2,8-双(三
氟甲基)-
4-喹啉甲醇或其药学上可接受的盐,该盐基本上不含其(−)-对映体,以减少副作用。